Clinical trials: Resistant Major Depression
Major Depressive Disorder, Depression
Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression: Comparing One Versus Two Doses of Psilocybin
The purpose of this study is to see if one or two doses of psilocybin is more effective in relieving depressive symptoms in patients with treatment-resistant depression (TRD).
- Conditions
- Major Depressive Disorder, Depression, Treatment-Resistant Depression, Mood Disorders
- Trial name
- PSI-1V2 (NCT06341426)
- Testing
- Single Psychedelic Dose Psilocybin, Two Psychedelic Doses Psilocybin
- Where
- 2 sites in Canada
- Volunteers
- 92 people
- Sponsor
- University Health Network, Toronto
Depression Chronic, Depression, Unipolar
Psychotherapeutic Augmentation of Brain Stimulation Effects
This study aims to investigate effectiveness and feasability of a 15-week group psychotherapeutic intervention as continuation treatment after electroconvulsive therapy in severely depressed patients.
- Conditions
- Depression Chronic, Depression, Unipolar, Treatment Resistant Depression
- Trial name
- PAUSE (NCT04159285)
- Testing
- EffEKTiv 2.0 group CBT as continuation treatment after ECT in depressed patients, Treatment as usual
- Where
- Germany
- Volunteers
- 16 people
- Sponsor
- Charite University, Berlin, Germany
Major Depression
Sequential Tranylcypromine (TC), TC + Dextroamphetamine and TC + Triiodothyronine for Refractory Depression
This pilot study will assess the efficacy of several sequential pharmacological treatments for patients with Refractory Depression.
- Trial name
- NCT00296686
- Testing
- Tranylcypromine, Dextroamphetamine, Triiodothyronine
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- New York State Psychiatric Institute
Depression
Buprenorphine for Late-Life Treatment Resistant Depression
The goals of this pilot study are to gather data about the safety and clinical effect of low-dose buprenorphine in older adults with treatment resistant depression.
- Trial name
- BUILD (NCT01071538)
- Testing
- Buprenorphine
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Pittsburgh
Depression, Major Depression
Evaluation of Three Continuation Therapies After ECT Concerning Efficacy and Cognition in Severly Depressed Patients
The purpose of this study is to evaluate three different continuation treatments after acute ECT concerning efficacy and impact on cognition in severly depressed patients.
- Trial name
- EffECT (NCT00437385)
- Testing
- TCAs, SSRIs, NARIs, SNRIs, Lithium, Electroconvulsive therapy, Cognitive behavioral group therapy
- Where
- Germany
- Volunteers
- 90 people
- Sponsor
- Charite University, Berlin, Germany
Depressive Disorder, Treatment-Resistant, Depressive Disorder, Major
Sevoflurane for Treatment-Resistant Depression
This study intends to carry out a prospective, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of subanesthetic sevoflurane for treatment-resistant depression.
- Trial name
- NCT05008939
- Testing
- Sevoflurane
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Shanghai First Maternity and Infant Hospital
Major Depressive Disorder
Deep rTMS for Treatment-Resistant Late-life Depression
In this study, the investigators will be examining the effects of the deep repetitive transcranial magnetic stimulation (rTMS) using the H1 coil in patients over the age of 60 who have been unable to tolerate or failed to respond…
- Trial name
- rTMS (NCT01860157)
- Testing
- Brainsway H1-Coil Deep TMS System
- Where
- Canada
- Volunteers
- 58 people
- Sponsor
- Centre for Addiction and Mental Health
Major Depressive Disorder, Treatment Resistant Depression
Open-Label Safety Study of AXS-05 in Subjects With Depression
An open-label, long-term, safety study of AXS-05 in patients with major depressive disorder (MDD), including treatment resistant depression.
- Conditions
- Major Depressive Disorder, Treatment Resistant Depression, Depression
- Trial name
- NCT04039022
- Testing
- AXS-05 (dextromethorphan and bupropion) oral tablets
- Where
- 51 sites in United States
- Volunteers
- 876 people
- Sponsor
- Axsome Therapeutics, Inc.
Major Depressive Disorder
Open Label Optimization Study
The goal of this observational study is to demonstrate effectiveness in the treatment of Major Depressive Disorder The primary objective is to assess the effectiveness in the treatment of Major Depressive Disorder using the CGI-I…
- Trial name
- OLO (NCT05819021)
- Testing
- SAINT® Neuromodulation System (NMS)
- Where
- 7 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- Magnus Medical
Treatment Resistant Major Depressive Disorder
Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders With TRD
This is a multi-site, randomized, open-label, effectiveness trial comparing three treatment arms for Major Depressive Disorder (MDD) patients with TRD who are currently on ongoing, stable and adequate antidepressant therapy…
- Trial name
- ASCERTAINTRD (NCT02977299)
- Testing
- Aripiprazole, Repetitive transcranial magnetic stimulation (rTMS), Venlafaxine XR
- Where
- 13 sites in United States, Canada
- Volunteers
- 278 people
- Sponsor
- Massachusetts General Hospital
Resistant Major Depression
Study of Transcranial Direct Current Stimulation (tDCS) as add-on Treatment for Resistant Major Depression
The purpose of the study is to investigate the effect of tDCS applied at the anodic left DLPFC of patients with resistant depression compared to patients treated with conventional therapy.
- Trial name
- DEPRESCO (NCT01428804)
- Testing
- transcranial Direct Current Stimulation (tDCS)
- Where
- France
- Volunteers
- 24 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Depressive Disorder, Treatment-Resistant
Healthy Lifestyle Promotion as Adjunctive Teletherapy for Treatment-resistant Major Depression
The main objective of the study will be to evaluate the effectiveness of an adjuvant lifestyle-based intervention for treatment-resistant patients with major depressive disorder.
- Trial name
- NCT04428099
- Testing
- Lifestyle change promotion program, Mindfullness based cognitive program, Written Information
- Where
- Spain
- Volunteers
- 186 people
- Sponsor
- University of the Balearic Islands
Depressive Disorder, Major
Ketamine Infusions for Major Depression Disorder
Ketamine has been safely used for induction and maintenance of anesthesia for decades and more recently has been used for chronic pain.
- Trial name
- Ketamie (NCT02219867)
- Testing
- Ketamine
- Where
- Israel
- Volunteers
- 10 people
- Sponsor
- Sheba Medical Center
Treatment Resistant Depression, Major Depressive Episode
University of Iowa Interventional Psychiatry Service Patient Registry
The purpose of this study is to examine the effects of interventional/procedural therapies for treatment-resistant depression (TRD) and Obsessive-Compulsive Disorder (OCD).
- Conditions
- Treatment Resistant Depression, Major Depressive Episode, Major Depression, Major Depressive Disorder
- Trial name
- NCT04480918
- Testing
- Electroconvulsive Therapy (ECT), Transcranial Magnetic Stimulation (TMS), Ketamine
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- Mark Niciu
Depression
SubGenual CG25 Deep Brain Stimulation in Severe Resistant Depression
Despite the availability of several treatments, a number of patients with major depression are refractory to therapeutical approaches and therefore suffer from chronic handicap.
- Trial name
- CG25 (NCT01834560)
- Where
- France
- Volunteers
- 5 people
- Sponsor
- University Hospital, Grenoble
Depression - Major Depressive Disorder
Effect of Neurofeedback and TMS
The goal of this clinical trial is to is to learn whether adding EEG neurofeedback (NFB) to repetitive transcranial magnetic stimulation (rTMS) is safe and feasible for adults with major depressive disorder (MDD).
- Trial name
- NCT07892287
- Testing
- Repetitive Transcranial Magnetic Stimulation, Alpha-down EEG Neurofeedback
- Volunteers
- 20 people
- Sponsor
- Massachusetts General Hospital
Depression
Safety and Efficacy of EVT 101 in Treatment-Resistant Depression
This study is a 4-week, randomized, double-blind, parallel-group, placebo-controlled monotherapy study in patients with treatment-resistant major depression.
- Trial name
- NCT01128452
- Testing
- EVT 101
- Where
- 14 sites in United States
- Volunteers
- 8 people
- Sponsor
- Janssen Research & Development, LLC
Major Depressive Disorder, Treatment Resistant Depression
Comparing Quetiapine XR Monotherapy and Augmentation With Lithium Augmentation in TRD Patients
The primary objective of the study is to evaluate the efficacy of Quetiapine extended release (XR) in combination with an selective serotonin reuptake inhibitor (SSRI) or Venlafaxine versus Lithium in combination with an…
- Trial name
- RUBY (NCT00789854)
- Testing
- Quetiapine XR, Lithium carbonate, SSRI/Venlafaxine
- Where
- 106 sites in Australia, Austria and 11 more
- Volunteers
- 688 people
- Sponsor
- AstraZeneca
Major Depression
Antidepressant Effects of NR2B in Major Depression
Purpose : This study will determine whether MK-0657, a selective NR2B Antagonist, can quickly improve symptoms of depressed mood, psychomotor retardation, poor motivation and reduced enjoyment of things in patients with major…
- Trial name
- NCT00472576
- Testing
- MK-0657
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Institute of Mental Health (NIMH)
Treatment Resistant Depression, Major Depressive Disorder
Biomarker-guided rTMS for Treatment Resistant Depression
Repetitive transcranial magnetic stimulation (rTMS) is a treatment for depression. The investigators are continuing to learn how to optimize outcomes from rTMS treatment.
- Trial name
- BioTMS (NCT04041479)
- Testing
- Repetitive Transcranial Magnetic Stimulation
- Where
- 2 sites in United States
- Volunteers
- 348 people
- Sponsor
- Weill Medical College of Cornell University